-
PurposeLentiviral RNAi vector for knockdown of LATS2 and LATS1. Co-expresses EmGFP as reporter
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 52085 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLenti4-EF/V5-DEST
-
Modifications to backboneEmGFP and LATS2/1 KD were inserted into pLenti-EF/V5-DEST from pcDNA 6.2-GW/miR vector.
-
Vector typeMammalian Expression, Lentiviral, RNAi
-
Selectable markersEmGFP
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberUnknown
Gene/Insert
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer EF1a-F
- 3′ sequencing primer pBABE-3 (Common Sequencing Primers)
Resource Information
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Co-cistronic expression of LATS2/1 pre-miRNA with EmGFP as reporter.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLenti-EmGFP-LATS2/1 KD was a gift from Yutaka Hata (Addgene plasmid # 52085 ; http://n2t.net/addgene:52085 ; RRID:Addgene_52085) -
For your References section:
Screening with a novel cell-based assay for TAZ activators identifies a compound that enhances myogenesis in C2C12 cells and facilitates muscle repair in the muscle injury model. Yang Z, Nakagawa K, Sarkar A, Maruyama J, Iwasa H, Bao Y, Ishigami-Yuasa M, Ito S, Kagechika H, Hata S, Nishina H, Abe S, Kitagawa M, Hata Y. Mol Cell Biol. 2014 Feb 18. 10.1128/MCB.01346-13 PubMed 24550007